Pharmaceutical Executive
Pharma's ultimate customers are overweight and can't sleep. Ever wonder what they say about that? The National Health and Wellness Survey asked.
Doctors aren't the only ones who decide if a patient gets a particular drug. Third-party payers have a say and, increasingly, so do patients. For nearly a decade, pharma companies have been talking directly to the people who ingest their products. But the patients aren't always talking back. When the 2005 National Health and Wellness Survey asked patients about their health, the results were astonishing—particularly when it comes to insomnia and obesity.
More than 77 million Americans are obese, and 66 million more are overweight. Nationwide, more than 95 million people report insomnia or difficulty sleeping. Women have more trouble sleeping than men, but men and women are equally likely to be severely overweight. Married adults tend to obesity more than single people, while lower-income Americans suffer most often from both insomnia and obesity.
Body Mass Index (weight in kilograms divided by the square of height in meters) (kg/m2) BMI is a measure of body fat based on height and weight that applies to both men and women. The National Institute of Health uses the following categories to interpret BMI.
About the Data In one of the most comprehensive online annual surveys in the world, 41,000 Americans and 36,000 Europeans fill out detailed questionnaires about their diagnosed and undiagnosed conditions in 75 therapeutic areas. The data here are drawn from American respondents in 2005, and are weighted by gender, age, race/ethnicity, and education. Staff epidemiologists projected the sample onto the total US population to create a representative portrait of the American market. Data were validated through comparisons to the US census and the National Health Interview Survey.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.